A recent study from the University of Hong Kong has found that a newer type of diabetes medicine may do more than just ...

Inside cells, two important enzymes act like small central regulatory hubs: dipeptidyl peptidase 8 and 9—DPP8/9 for short. Among other things, they regulate inflammatory reactions and influence ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

In patients with type 2 diabetes, the risk for chronic kidney disease differed among users of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylurea.

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Type 2 diabetes mellitus (T2DM) is a major public health challenge in India, with an estimated 101 million individuals ...

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

Initiation of the Phase 2 EMPOWER trial of ARD-201 for the treatment of obesity and obesity-related conditions as a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor is ...

comparing patients with type 2 diabetes between 2007 and 2023 for the risk of thyroid cancer among GLP1-RA users compared with dipeptidyl peptidase-4 inhibitors (DPP-4is). The investigators examined ...